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1000-1420 PCI’s annually with operators using a default femoral (F) access for PCI then
progressing to a R approach. Data on patient demographics, procedure details, fluoros-
copy time and radiation doses and outcomes were collected from internal and national
databases.
Results: 6575 patients underwent PCI over a 5 yr period. In 5yrs, R access increased from
31.4% to 90%(p0.0001). The access change from was seen amongst all operators and
patient groups. The x-over rate from R to F access to finish the PCI was 1.5% compared
to a F to R x-over of 6.2%(pns). There was an increase in fluoroscopy (R)1097.8 vs
(F)851.8 sec (p0.001) and radiation dose (R)63.9vs(F)57.3cGycm2(p0.01) during yr1
when operators went from 32 to 67% R approach. There were no differences in
fluoroscopy time (R)919.9vs.(F)896.3sec,pns) and radiation dose(R)62.7vs(F)62.7
cGycm2,pns in yr2	3.In yr4	5 when R use was 90% of cases; fluoroscopy time
(R)919.4vs(F)1124.4sec, P0.007 and radiation dose(R)70.4vs(F)86.4cGycm2,P0.01
decreased. Over 5yrs, vascular complications and major bleeding were higher in the F
group (2.32%vs1.00%, p0.001; 1.12% vs 0.10%, p0.0001) while length of stay was
shorter in the R group 0.75 vs 1.07 days, p0.0001).
Conclusions: Adoption of the R approach in centres performing PCI predominantly via
the F route is feasible within 5yrs and translates into both clinical and economic benefits
with reductions in hospital stay and vascular/bleeding complications. There is however a
‘learning curve’ which results in increased fluoroscopy time and radiation doses in the
initial phases, which is reversed once the radial approach is used in 60% of PCI cases.
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Background: Transradial approach (TRA) for coronary angiography and interventions
was shown to be associated with a striking reduction in the rate of vascular access site
complications (VASC) as compared to transfemoral approach (TFA). As a result, the
prevalence of TRA is increasing worldwide, with a growing proportion of physicians who
select TRA as their preferred approach in the vast majority of cases (so called “radialists”).
A possible drawback of this behaviour could be the loss of expertise in TFA, potentially
leading to an increased rate of VASC when TFA is needed due to clinical (e.g. cardiogenic
shock) or technical reasons (e.g. need for large guiding catheters).
Methods: We designed a prospective, single center, 3-years registry aimed to investigate
whether high-volume TRA operators (HTRAop; 75% TRA) experience an increased
rate of femoral VASC as compared to lower-volume TRA operators (LTRAop; 75%
TRA). All femoral VASC requiring interventions or prolonging hospital stay were
recorded.
Results: Between May 2009 and May 2012 2749 procedures, of which 1255 percuta-
neous coronary interventions (PCI), were performed at our Institution by 4 main
operators. HTRAop performed 1466 procedures, whereas LTRAop performed 1283
procedures. The rate of TRA was 78.6% (range 76.7-80.6) in HTRAop and 61.7%
(61.3-62.2) in LTRAop (p0.001). The rate of PCI was 47.9% in HTRAop vs 43.1% in
LTRAop (p0.05). The majority of procedures were performed with 6F sheaths; 4
procedures were performed with 5F and 150 with 7F sheaths. Vascular closure devices
were only used in 25 patients (0.91%). We observed 12 femoral VASC: 8 pseudoaneu-
rysms (6 of which treated by echo-guided compression, the remaining by surgery), 3 cases
of limb ischemia, treated by surgery, and 1 case of femoral vein thrombosis. In TFA
procedures, the rate of femoral VASC was not different between HTRAop and LTRAop
(0.96% vs 1.84%; p0.38). Overall, less femoral VASC were observed in HTRAop as
compared to LTRAop (0.20% vs 0.70%; p0.05).
Conclusions: Our data do not support the concern that high-volume TRA operators could
experience a higher rate of femoral VASC when performing TFA. A higher TRA rate is
actually associated with less femoral VASC.
TCT-29
Radial versus femoral access for coronary angiography and intervention in
patients with acute coronary syndromes: results of the Zwolle Myocardial
Infarction Study Group
Rik Hermanides1, Jan Paul Ottervanger1, Jan-Henk Dambrink1,
Marcel Gosselink1, Evelien Kolkman2, Vincent Roolvink1, Jan Hoorntje1,
Arnoud van ’t Hof1
1Isala Klinieken, Zwolle, Netherlands, 2Diagram Zwolle, Zwolle, Netherlands
Background: Trials have suggested that radial access for percutaneous coronary
intervention (PCI) reduces vascular complications and bleeding compared with femoral
access. Aim of this study was to assess the efficacy and safety of radial access versus
femoral access in patients (pts) with acute coronary syndromes (ACS) who underwent
coronary angiography with possible intervention.
Methods: This is a single-centre, large, prospective observational registration of all
STEMI and NSTEMI pts who underwent coronary angiography and/or (primary) PCI in
the period January 2010–December 2011. Primary endpoint was in-hospital non CABG-
related major and minor bleeding. All safety- and clinical parameters, including bleeding
were performed by 2 independent investigators.
Results: Of the 2295 ACS patients, 56.2% were diagnosed with STEMI and 43.8% with a
NSTEMI on admission. Coronary angiography was performed in 2042/2295 (89%) and in
334/2042 pts (16%) by radial access. PCI was performed in 1506/2033 (74.1%) of the pts. No
differences in baseline or angiographic characteristics were present between radial vs femoral
access patients except for diagnosis of STEMI: 48.5% vs 61.0%, p0.001, IABP use: 0.9%
vs 7.1%, p0.001, and Killip class2: 6.6% vs 12.8%, p0.001). The primary endpoint
occurred less often in the radial group as compared to the femoral group (0.9% vs 3.4%,
p0.014), especially in the subgroup of pts with a moderate, high or very high CRUSADE
bleeding score (0.0% vs 7.5%, p0.012). 30-day mortality was significantly lower in the radial
group as compared to the femoral group (1.7% vs 4.8%, p0.014). However, radial access
was neither an independent predictor for the primary endpoint (HR 0.417; 95% CI,
0.125–1.316, p0.136), as for 30-day mortality (HR 0.50; 95% CI, 0.182–1.415, p0.195).
Conclusions: Although radial access significantly reduced in-hospital non CABG-related
major and minor bleeding and 30-day mortality as compared to femoral access, the
difference was no longer significant after multivariate correction for differences in baseline
and angiographic characteristics between the groups.
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Background: Bleeding during emergency percutaneous coronary intervention (PCI)
predicts reduced survival. Radial artery access potentially reduces the risk of bleeding. We
aimed to assess short-term and medium-term outcomes following radial and femoral
artery access for primary or rescue percutaneous coronary intervention (PCI).
Methods: A retrospective cohort study in Scotland, UK. All 4534 patients who had
primary or rescue PCI in Scotland between April 2000 and March 2009 were identified
using the Scottish Coronary Revascularisation Register. The outcome measures were
procedural success; peri-procedural complications; 30-day and 1-year mortality, myocar-
dial infarction or stroke and long-term mortality.
Results: Use of the radial approach increased from no cases in 2000 to 924 (80.5%) in
2009 (p0.001). Patients in whom the radial approach was used were more likely to be
male (p0.041) and to have multiple comorbidities (p0.001), including hypertension
(p0.001) and left ventricular dysfunction (p0.001). They were less likely to have renal
impairment (p0.017), multi-vessel coronary disease (p0.001) and cardiogenic shock
(p0.001). In multivariable analyses, use of radial artery access was associated with
greater procedural success (adjusted OR 1.89, 95% CI 1.26 - 2.82, p0.002) and a lower
risk of any complications (adjusted OR 0.67, 95% CI 0.51 - 0.87, p0.001) or access site
bleeding complications (adjusted OR 0.21, 0.08 - 0.56, p0.002), as well as a lower risk
of myocardial infarction (adjusted OR 0.66, 95% CI 0.51-0.87, p0.003) or death within
30 days (adjusted OR 0.51, 95% CI 0.04 - 0.52, p0.001). The differences in myocardial
infarction and death remained significant up to 9 years of follow-up.
Conclusions: Compared with femoral artery access, use of the radial artery for primary
or rescue PCI is associated with improved clinical outcomes.
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Background: Peri-procedural bleeding complications have been associated with a worse
outcome in patients undergoing percutaneous coronary intervention (PCI), especially in
the context of acute coronary syndromes (ACSs). This study aims to assess if the selection
of transradial approach to perform PCI still represents an advantage in terms of bleeding
reduction also in patients needing intra-aortic balloon pump (IABP) support.
Methods: We retrospectivelly analyzed 241 consecutive patients receiving IABP support
during PCI in four independent high-volume centers. Patients were further divided in two
groups: 116 patients receiving double femoral access (FF) and 125 receiving both radial
and femoral (RF) approaches. Primary end-points were assessment of in-hospital Net
Adverse Clinical Events (NACE, composite of post-procedural bleeding, cardiac death,
myocardial infarction, target lesion revascularization or stroke) and bleeding (defined
according to ARC classification) rates.
Results: Median patient age was 71 [1st-3rd quartile 61-79] years and diagnosis at
admission was ACS in 91% of patients, including acute ST elevation myocardial
infarction in 73%. High-risk patient profile included Killip class 3-4 presentation in 78%,
mean systolic arterial pressure 90 [70-100] mmHg, mean left ventricle ejection fraction
30% [25-40] and multivessel coronary artery disease in 70% involving left main trunk in
26% of cases. Cumulative 30-day NACE rate was 54% (130), while a bleeding occured
in 29% of patients. NACEs were more frequent in the FF group when compared to the RF
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group (67% vs. 41%, p0.01). In particular this difference stemmed from an increase of
access site-related bleeding (21% vs. 7%, p0.01) and cardiac death (41% vs. 25%,
p0.01) in the FF group. The adjusted multivariable regression analysis confirmed radial
approach as independent outcome predictor (OR 0.53 CI 95% 0.29-0.96, p0.037).
Conclusions: Transradial approach use for PCI requiring IABP support positively
impacts periprocedural outcome by means of a significant access-site-related bleeding and
cardiac death prevention. Thus, its use seems strongly recommended in patients at
increased risk of bleeding, such as those admitted for an ACS.
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Background: There has been a significant increase in use of transradial access (TRA) for
PCI in the UK. Early on in the TRA learning curve, procedures are associated with more
catheter exchanges, longer screening times and with more contrast use. These factors are
all associated with increased risk of periprocedural neurological complications (NC).
Using the British Cardiovascular Intervention Society PCI database we assessed changes in
NC through a period of transition during which radial access became the dominant access for
PCI.
Methods: This study includes data collected by the British Cardiovascular Intervention
Society under the auspices of the Central Cardiac Audit Database. We performed a
retrospective analysis of the BCIS database between January 2006 and December 2010.
The data was split into 2 cohorts based on access site: either radial or femoral (mixed
access site use and other access sites were excluded from the analysis). A NC was defined
as a periprocedural TIA, ischemic stroke or hemorrhagic stroke.
Results: Between 2006 and 2010 a total of 348,092 procedures were recorded exclusively
using either transradial (TRA) or tansfemoral (TFA) access. Over 5 years, the use of TRA for
PCI increased from 17.1% to 50.8% of procedures. There was no difference in the incidence
of NC during this period. Following multivariate analysis of the whole 5 year cohort, no
difference in NC was observed between TRA and TFA (HR 1.005 CI 0.81-1.248: p0.96).
Conclusions: These results are reassuring and suggest that a switch from TFA to TRA
is not associated with any increased risk of periprocedural neurological complications.
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Background: The everolimus-eluting Bioresorbable Vascular Scaffold (Absorb) is a
novel approach to treating coronary lesions. A persistent inflammatory response, fibrin
deposition and delayed endothelialisation have been reported with overlapping first-
generation drug eluting stents. We report optical coherence tomography and histological
findings in a porcine coronary artery model after implantation of overlapping Absorb or
second-generation everolimus-eluting metallic platform stents (XIENCE V [XV]).
Methods: 41 overlapping Absorb and overlapping XV devices (3.012 mm) were
implanted in the main coronary arteries of 17 non-atherosclerotic pigs with a balloon
artery ratio of 1.1:1 (10% over-stretch). Implanted coronary arteries were evaluated by
OCT at 28 (Absorb: n11, XV: n 7) and 90 days (Absorb: n11, XV: n 8), with
immediate histological evaluation following euthanasia at the same time points. One
animal from each time point was evaluated with scanning electron microscopy alone.
Results: 1407 cross-sections were analysed by OCT and 148 cross-sections analysed
histologically. At 28 days in the overlap, OCT analyses indicated 80.1% of Absorb struts
and 99.4% of XV struts to be covered (p0.0001), corresponding to histological
observations of struts with cellular coverage of 75.4% and 99.6% respectively (p0.001).
Uncovered struts were almost exclusively related to the presence of ’stacked’ Absorb
struts, i.e. with a direct overlay configuration. At 90 days overlapping Absorb and
overlapping XV struts demonstrated99% strut coverage by OCT and histology, with no
evidence of a significant inflammatory process, and comparable % volume obstructions.
Conclusions: In porcine coronary arteries implanted with overlapping Absorb, strut
coverage is dependent on the overlay configuration of Absorb struts at 28 days and not at
90 days. The potential clinical implications of increased strut thickness in the management
of long lesions & coronary bifurcations may have important clinical (e.g. duration of
antiplatelet therapy) and design considerations (e.g. longer devices & the requirement of
dedicated bifurcation devices to avoid overlapping the device) for current and future
devices with bioresorbable platforms.
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Background: The safety and performance of the Absorb Bioresorbable Vascular
Scaffold (BVS) System (Abbott Vascular, Santa Clara, CA) has been previously
established in 131 patients from Cohort A and Cohort B of the First-in-Man ABSORB
trial. Results out to 2 years have been presented in 101 patients from the ABSORB Cohort
B trial. At 12 months, the MACE rate was 6.9%, with no scaffold thrombosis reported,
which was sustained out to 2 years with a MACE rate of 9.0%. Following this trial,
ABSORB EXTEND was initiated as a global continued access study (outside of the US)
to expand experience with the Absorb BVS to different geographies. Additionally, patients
were treated for longer coronary lesions than those in the ABSORB trial using either
longer scaffold lengths or planned overlap of the Absorb BVS.
Methods: ABSORB EXTEND is a prospective, single-arm, open-label clinical study that
is planning to enroll up to 1,000 subjects at up to 100 sites. Included are patients with
lesions  28 mm in length and reference vessel diameter of 2.0 - 3.3 mm (as assessed by
on-line QCA or IVUS). Treatment of a maximum of two de novo native coronary artery
lesions, each in a different epicardial vessel, is permitted.
Results: Interim 12-month data in the first 250 patients enrolled in ABSORB EXTEND
will be available for the first time in October 2012 and will provide additional data on the
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